Pfizer to make more Prevenar 13 as WHO expands prequalification
This article was originally published in Scrip
Executive Summary
Pfizer said it is increasing its manufacturing capabilities for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), after the World Health Organization (WHO) expanded the current 'prequalification' of the product to adults aged over 50.